The Predictive Value of FDG PET/CT for Determining Progression-Free Survival in Advanced Stage III–IV BRAF-Mutated Melanoma Patients Treated With Targeted Therapy—What Can Be Learned From Progression?

Bernies van der Hiel,Else A. Aalbersberg,Alfons J.M. van den Eertwegh,Linda J. de Wit-van der Veen,Marcel P.M. Stokkel,Marta Lopez-Yurda,Ronald Boellaard,Ellen W. Kapiteijn,Geke A.P. Hospers,Maureen J.B. Aarts,Filip Y.F.L. de Vos,Marye J. Boers-Sonderen,Astrid A.M. van der Veldt,Jan Willem B. de Groot,John B.A.G Haanen

DOI: https://doi.org/10.1097/rlu.0000000000004988

IF: 10.6

2024-01-06

Clinical Nuclear Medicine

Abstract:The aims of this study were to investigate whether (early) PERCIST response monitoring with 18 F-FDG PET/CT is predictive for progression-free survival (PFS) in unresectable stage III or IV melanoma patients treated with BRAF/MEK inhibitor (MEKi) and to define dissemination patterns at progression with a lesion-based evaluation in direct comparison to baseline to improve our understanding of 18 F-FDG PET/CT during BRAF/MEKi.

radiology, nuclear medicine & medical imaging